BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 25410484)

  • 1. Shift in GATA3 functions, and GATA3 mutations, control progression and clinical presentation in breast cancer.
    Cohen H; Ben-Hamo R; Gidoni M; Yitzhaki I; Kozol R; Zilberberg A; Efroni S
    Breast Cancer Res; 2014 Nov; 16(6):464. PubMed ID: 25410484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. C1orf106, an innate immunity activator, is amplified in breast cancer and is required for basal-like/luminal progenitor fate decision.
    Ma J; Liu C; Yang D; Song J; Zhang J; Wang T; Wang M; Xu W; Li X; Ding S; Zhan J; Zhang H
    Sci China Life Sci; 2019 Sep; 62(9):1229-1242. PubMed ID: 31376015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GATA3 mutations define a unique subtype of luminal-like breast cancer with improved survival.
    Jiang YZ; Yu KD; Zuo WJ; Peng WT; Shao ZM
    Cancer; 2014 May; 120(9):1329-37. PubMed ID: 24477928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progesterone receptor activation downregulates GATA3 by transcriptional repression and increased protein turnover promoting breast tumor growth.
    Izzo F; Mercogliano F; Venturutti L; Tkach M; Inurrigarro G; Schillaci R; Cerchietti L; Elizalde PV; Proietti CJ
    Breast Cancer Res; 2014 Dec; 16(6):491. PubMed ID: 25479686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gata-3 negatively regulates the tumor-initiating capacity of mammary luminal progenitor cells and targets the putative tumor suppressor caspase-14.
    Asselin-Labat ML; Sutherland KD; Vaillant F; Gyorki DE; Wu D; Holroyd S; Breslin K; Ward T; Shi W; Bath ML; Deb S; Fox SB; Smyth GK; Lindeman GJ; Visvader JE
    Mol Cell Biol; 2011 Nov; 31(22):4609-22. PubMed ID: 21930782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CDK inhibitor p18(INK4c) is a downstream target of GATA3 and restrains mammary luminal progenitor cell proliferation and tumorigenesis.
    Pei XH; Bai F; Smith MD; Usary J; Fan C; Pai SY; Ho IC; Perou CM; Xiong Y
    Cancer Cell; 2009 May; 15(5):389-401. PubMed ID: 19411068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GATA3 expression in advanced breast cancer: prognostic value and organ-specific relapse.
    McCleskey BC; Penedo TL; Zhang K; Hameed O; Siegal GP; Wei S
    Am J Clin Pathol; 2015 Nov; 144(5):756-63. PubMed ID: 26486740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GATA3 cooperates with PARP1 to regulate CCND1 transcription through modulating histone H1 incorporation.
    Shan L; Li X; Liu L; Ding X; Wang Q; Zheng Y; Duan Y; Xuan C; Wang Y; Yang F; Shang Y; Shi L
    Oncogene; 2014 Jun; 33(24):3205-16. PubMed ID: 23851505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer-specific mutation of GATA3 disrupts the transcriptional regulatory network governed by Estrogen Receptor alpha, FOXA1 and GATA3.
    Takaku M; Grimm SA; De Kumar B; Bennett BD; Wade PA
    Nucleic Acids Res; 2020 May; 48(9):4756-4768. PubMed ID: 32232341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutant GATA3 Actively Promotes the Growth of Normal and Malignant Mammary Cells.
    Emmanuel N; Lofgren KA; Peterson EA; Meier DR; Jung EH; Kenny PA
    Anticancer Res; 2018 Aug; 38(8):4435-4441. PubMed ID: 30061207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GATA3 protein as a MUC1 transcriptional regulator in breast cancer cells.
    Abba MC; Nunez MI; Colussi AG; Croce MV; Segal-Eiras A; Aldaz CM
    Breast Cancer Res; 2006; 8(6):R64. PubMed ID: 17078870
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Shahi P; Wang CY; Lawson DA; Slorach EM; Lu A; Yu Y; Lai MD; Gonzalez Velozo H; Werb Z
    Proc Natl Acad Sci U S A; 2017 Mar; 114(12):3169-3174. PubMed ID: 28258171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DACH1 suppresses breast cancer as a negative regulator of CD44.
    Xu H; Yu S; Yuan X; Xiong J; Kuang D; Pestell RG; Wu K
    Sci Rep; 2017 Jun; 7(1):4361. PubMed ID: 28659634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GATA3 and TRPS1 are distinct biomarkers and prognostic factors in breast cancer: database mining for GATA family members in malignancies.
    Lin HY; Zeng D; Liang YK; Wei XL; Chen CF
    Oncotarget; 2017 May; 8(21):34750-34761. PubMed ID: 28423734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein kinase A-dependent synergism between GATA factors and the nuclear receptor, liver receptor homolog-1, regulates human aromatase (CYP19) PII promoter activity in breast cancer cells.
    Bouchard MF; Taniguchi H; Viger RS
    Endocrinology; 2005 Nov; 146(11):4905-16. PubMed ID: 16109788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ELK3-GATA3 axis modulates MDA-MB-231 metastasis by regulating cell-cell adhesion-related genes.
    Kim KS; Kim J; Oh N; Kim MY; Park KS
    Biochem Biophys Res Commun; 2018 Apr; 498(3):509-515. PubMed ID: 29510139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of function of GATA3 regulates FRA1 and c-FOS to activate EMT and promote mammary tumorigenesis and metastasis.
    Liu X; Bai F; Wang Y; Wang C; Chan HL; Zheng C; Fang J; Zhu WG; Pei XH
    Cell Death Dis; 2023 Jun; 14(6):370. PubMed ID: 37353480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heterarchy of transcription factors driving basal and luminal cell phenotypes in human urothelium.
    Fishwick C; Higgins J; Percival-Alwyn L; Hustler A; Pearson J; Bastkowski S; Moxon S; Swarbreck D; Greenman CD; Southgate J
    Cell Death Differ; 2017 May; 24(5):809-818. PubMed ID: 28282036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Common genetic variation in GATA-binding protein 3 and differential susceptibility to breast cancer by estrogen receptor alpha tumor status.
    Garcia-Closas M; Troester MA; Qi Y; Langerød A; Yeager M; Lissowska J; Brinton L; Welch R; Peplonska B; Gerhard DS; Gram IT; Kristensen V; Børresen-Dale AL; Chanock S; Perou CM
    Cancer Epidemiol Biomarkers Prev; 2007 Nov; 16(11):2269-75. PubMed ID: 18006915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GATA3 Truncating Mutations Promote Cistromic Re-Programming In Vitro, but Not Mammary Tumor Formation in Mice.
    Cornelissen LM; de Bruijn R; Henneman L; Kim Y; Zwart W; Jonkers J
    J Mammary Gland Biol Neoplasia; 2019 Sep; 24(3):271-284. PubMed ID: 31218575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.